CSIMarket
 
Paratek Pharmaceuticals Inc   (PRTK)
Other Ticker:  
 
 
Price: $2.2300 $0.04 1.826%
Day's High: $2.24 Week Perf: 1.83 %
Day's Low: $ 2.19 30 Day Perf: 2.53 %
Volume (M): 4,764 52 Wk High: $ 2.91
Volume (M$): $ 10,625 52 Wk Avg: $2.11
Open: $2.19 52 Wk Low: $1.34



 Market Capitalization (Millions $) 127
 Shares Outstanding (Millions) 57
 Employees 200
 Revenues (TTM) (Millions $) 167
 Net Income (TTM) (Millions $) -66
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Paratek Pharmaceuticals Inc
Paratek Pharmaceuticals Inc is a US-based biopharmaceutical company that develops innovative therapies for the treatment of infectious diseases and other serious conditions. The company was founded in 1996 with a focus on developing antibiotics to address the growing problem of antibiotic-resistant bacteria.

The company's lead product is NUZYRA, a once-daily oral and intravenous antibiotic that is approved for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). NUZYRA is unique in that it is effective against a wide range of bacteria, including those that are resistant to other antibiotics, such as MRSA.

In addition to NUZYRA, Paratek is also developing a second antibiotic, SEYSARA, for the treatment of acne vulgaris. SEYSARA is a once-daily oral antibiotic that targets a specific type of bacteria that is commonly associated with acne.

Paratek has a strong pipeline of additional antibiotics in development, including drugs targeting gram-negative bacteria, which are notoriously difficult to treat. The company's approach to drug development is focused on using innovative technologies and approaches to discover and develop drugs that are effective against drug-resistant bacteria.

Paratek has partnerships and collaborations with a number of academic and commercial organizations, including the US Department of Defense, which is funding the development of a new class of antibiotics for use in biodefense.

The company is headquartered in Boston, Massachusetts, and has additional offices in King of Prussia, Pennsylvania, and Zug, Switzerland. Paratek has a workforce of approximately 160 employees.

Overall, Paratek Pharmaceuticals is a pioneering biopharmaceutical company that is committed to developing innovative therapies for the treatment of infectious diseases and other serious conditions. With a strong pipeline of antibiotics in development and a focus on using cutting-edge technologies and approaches to drug discovery, Paratek is poised to make a significant impact on the field of antibiotic development and change the way we treat drug-resistant infections.


   Company Address: 75 Park Plaza Boston 2116 MA
   Company Phone Number: 807-6600   Stock Exchange / Ticker: NASDAQ PRTK
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals Inc Faces a $-0.35 Per Share Shortfall Despite Strong Revenue Surge in First Quarter of Fiscal Year 2023

Paratek Pharmaceuticals Inc Reports Strong Surge in Revenue for First Quarter of Fiscal Year 2023, Despite Net Shortfall
Paratek Pharmaceuticals Inc, a leading biopharmaceutical company, announced that it has experienced a massive surge in revenue by 25.643% to $31.24 million in the first quarter of fiscal year 2023. This is compared to the same financial reporting period a year ago. The revenue increase is a testament to the company's outstanding performance in the competitive pharmaceutical industry. This financial achievement came amidst the global pandemic, which has disrupted many businesses and impacted the overall economy.
Despite the impressive revenue surge, Paratek Pharmaceuticals Inc experienced a significant net shortfall of $-20.143 million for the first quarter of fiscal year 2023. This is higher compared to the $-17.910 million shortfall reported in the same period last year. The company has lost money at $-0.35 per share, a decline from the previous year's report of $-0.11 per share. Furthermore, the Revenue Tumbled by -58.659 % from $75.56 million in the prior period, indicating that the business landscape is challenging.






 

Paratek Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com